John H. Johnson has served as the Chairman of our board of directors since November 2010. Mr. Johnson is the president and chief executive officer of Dendreon Corporation, or Dendreon (NASDAQ: DNDN), a position he has held since February 2012. Mr. Johnson has served as a member of Dendreon's board of directors since August 2011. Prior to joining Dendreon, Mr. Johnson was the chief executive officer of Savient Pharmaceuticals, Inc., where he has also served as a member of its board of directors since January 2011. Before joining Savient Pharmaceuticals, Inc., Mr. Johnson served as president of Eli Lilly & Company's Oncology Unit, following the company's 2008 acquisition of Imclone Systems, Inc., where he served as chief executive officer. Prior to joining Imclone, he served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Prior to assuming that role, Mr. Johnson held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp., as well as positions at Pfizer, Inc. Mr. Johnson received his bachelor's degree from East Stroudsburg University of Pennsylvania. He is currently a member of the board of directors for Savient Pharmaceuticals, Inc., and Cempra Pharmaceuticals, Inc.
